AstraZeneca Trial Miss Leaves Citi Bullish on Broader Pipeline

AstraZeneca’s latest oncology setback removes a potential multibillion-pound expansion for Etcamah, but Citi says the failure does not fracture its broader investment case.

The drugmaker said September 11 that the Phase 3 SERENA-4 trial missed its primary endpoint in previously untreated patients with estrogen receptor-positive, HER2-negative advanced breast cancer. Etcamah, also known as camizestrant, produced a numerical improvement in progression-free survival when paired with Pfizer’s Ibrance, but the result was not statistically significant against anastrozole plus Ibrance. The study enrolled 1,371 patients.

That distinction matters commercially. SERENA-4 was testing Etcamah in the broad first-line population, where success could have transformed the drug from a targeted product into a major breast cancer franchise. Instead, AstraZeneca is left with a narrower opportunity created by its recent U.S. accelerated approval.

The Food and Drug Administration cleared Etcamah on September 4 for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer when an ESR1 resistance mutation emerges during treatment with an aromatase inhibitor and a CDK4/6 inhibitor. The label covers combinations with abemaciclib, palbociclib or ribociclib. FDA documents put median progression-free survival at 16 months for the Etcamah combination, versus 9.2 months for continued aromatase-inhibitor therapy, while requiring confirmatory evidence because the approval relies on an intermediate endpoint.

Citi retained its buy rating and £178 price target on AstraZeneca, arguing that investors had already approached SERENA-4 cautiously. The bank estimates the miss cuts roughly 2.5% from its valuation of camizestrant, a reduction it says is largely offset by the drug’s approved ESR1-mutated use. AstraZeneca’s shares moved little after the initial announcement, following a roughly 3% after-hours decline on September 11.

The result also deepens doubts around oral selective estrogen receptor degraders in first-line disease. Roche’s giredestrant failed in a comparable setting earlier this year, making the class’s biology harder to underwrite at the front end of treatment. Citi’s argument is that the bad news clears an overhang, leaving investors to focus on later-2026 and 2027 readouts across AstraZeneca’s wider pipeline, including lung-cancer and antibody-drug-conjugate programs. The company said its early-stage breast cancer studies remain active.